

The paragraph at page 1, lines 10-13 has been amended as follows:

### CROSS-REFERENCE TO RELATED APPLICATIONS

C1  
This is a divisional application of co-pending application Serial No. 09/109,207, filed on June 30, 1998, now U.S. patent No. 6,172,213 which was a non-provisional application filed under 37 CFR 1.53(b), claiming priority under USC Section 119(e) to Provisional Application Serial No. 60/051,554, filed July 2, 1997.

### In the claims:

Please amend Claims 32-39, 41 and 46 as follows:

32. (Twice Amended). A composition of an improved anti-IgE antibody or IgE binding fragment thereof in combination with an adjunct immunosuppressive agent, wherein the improved anti-IgE antibody or IgE binding fragment thereof comprises:

- (a) the heavy and light chains of E26 (SEQ ID NOs:15-16);
- (b) the heavy and light chains of E27 (SEQ ID NOs:17-18); or
- (c) antigen binding fragments of (a) or (b).

33. (Twice Amended). The composition of Claim 32, wherein the immunosuppressive agent is selected from the group consisting of azathioprine, cyclophosphamide, bromocryptine and glutaraldehyde.

34. (Twice Amended). The composition of Claim 32, wherein the immunosuppressive agent is a glucocorticosteroid

C2  
Sub D1  
35. (Twice Amended). The composition of Claim 32, wherein the immunosuppressive agent is selected from the group consisting of: cyclosporin A; anti-CD3; anti-CD4 and anti-CD4a.

36. (Twice Amended). The composition of Claim 32, wherein the immunosuppressive agent is selected from the group consisting of: a soluble peptide containing an LFA-3 binding domain; streptokinase; TGF- $\beta$ ; streptodornase; deoxyspergualin; rapamycin and T-cell receptor.

37. (Amended). The composition of Claim 32, wherein the improved anti-IgE antibody comprises the heavy and light chain sequences of E26 (SEQ ID NOs:15-16).

C3  
38. (Amended). The composition of Claim 32, wherein the improved IgE binding fragment comprises an E26 sequence selected from the group consisting of: an Fab fragment (SEQ ID NOs:19-20; an sFv fragment (SEQ ID NO:22) and an F(ab')<sub>2</sub> fragment (SEQ ID NOs: 24-25).

39. (Amended). The composition of Claim 32, wherein the improved IgE binding fragment comprises an E27 sequence selected from the group consisting of: an Fab fragment (SEQ ID NOs: 19 and 21); an sFv fragment (SEQ ID NO:23) and an F(ab')<sub>2</sub> fragment (SEQ ID NOs: 24 and 26).

C4  
41. (Amended). The composition of Claim 32, wherein the improved anti-IgE antibody comprises the heavy and light chains of E27 (SEQ ID NOs: 17-18).

C5  
Sub D3  
46. (Amended). The composition of Claim 45, wherein the immunosuppressive agent is an antibody selected from the group consisting of: anti-interferon- $\gamma$ , anti-interferon- $\beta$ , or anti-interferon- $\alpha$ ; anti-tumor necrosis factor- $\alpha$ , anti-tumor necrosis factor- $\beta$ , anti-interleukin-2, anti-IL-2 receptor antibody and anti-CD3T4.